Weinhäuser et al. found that the poor OS prediction associated with high CD163/CD206 mRNA expression is not necessarily driven by intrinsic AML biology but could be attributed to the presence of an AML tumor supportive niche39,52,53. The gene discussed is CD163; the disease is acute myeloid leukemia.